Remove Biobanking Remove Containment Remove Genetics Remove Research
article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. Why should research be any different? with their priorities.

article thumbnail

New Research Reveals How Air Pollution May Trigger Lung Cancer

XTalks

Researchers at the Francis Crick Institute and University College London in the UK have found how air pollution can trigger the activation of cells with existing genetic mutations to form cancer. The researchers propose that particulate matter 2.5 The new research shows that air pollutants can be that ‘second hit.’

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug discovery hotspots: Focus on Qatar

Drug Discovery World

Within this, Qatar is emerging as a country which is actively seeking to bolster its drug discovery and development sectors, through high levels of spending and investment into local research programmes. Qatar is a small country but faces many of the same healthcare problems that Western countries currently face.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Generation of strong research dataset cohorts must begin with high-quality clinical samples. Biobanks are used for the coordination of high-yield patient sample collection. The webinar highlighted the importance of maximizing utility and sustainability for the long-term success of biorepositories and biobanks.

article thumbnail

WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE

The Pharma Data

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

The RNA interference specialist says its researchers and collaborators have identified mutations in a gene called INHBE that are associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide. . Image by Bruno /Germany from Pixabay .

article thumbnail

Collaboration between AbbVie, Biogen and Pfizer creates world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease

The Pharma Data

The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).